Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic diseases, has announced its participation in two major healthcare investor conferences in June 2025:
- The Jefferies Global Healthcare Conference on June 5 at 8:10 a.m. ET in New York, featuring a fireside chat and one-on-one meetings
- The Goldman Sachs Global Healthcare Conference on June 11 at 10:40 a.m. ET in Miami, also including a fireside chat and one-on-one meetings
Both fireside chat sessions will be available via webcast on the company's investor relations website, with replays accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GPCR declined 2.94%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June.
Jefferies Global Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/time: Thursday, June 5 at 8:10 a.m. ET
Location: New York, NY
Goldman Sachs Global Healthcare Conference
Format: Fireside chat and 1x1 meetings
Date/time: Wednesday, June 11 at 10:40 a.m. ET
Location: Miami, FL
The live and archived webcasts of the fireside chats will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and a replay will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
What investor conferences will Structure Therapeutics (GPCR) attend in June 2025?
When is Structure Therapeutics' (GPCR) presentation at the Jefferies Healthcare Conference?
How can investors access Structure Therapeutics' (GPCR) conference presentations?
What type of company is Structure Therapeutics (GPCR)?
